ORIC Pharmaceuticals, Inc.
ORIC
$8.60
-$0.23-2.61%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.45% | 15.14% | 13.92% | 14.48% | 12.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.24% | 0.08% | 9.85% | 19.62% | 28.51% |
| Operating Income | -2.24% | -0.08% | -9.85% | -19.62% | -28.51% |
| Income Before Tax | -1.77% | -1.27% | -12.85% | -23.89% | -30.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.77% | -1.27% | -12.85% | -23.89% | -30.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.77% | -1.27% | -12.85% | -23.89% | -30.56% |
| EBIT | -2.24% | -0.08% | -9.85% | -19.62% | -28.51% |
| EBITDA | -2.23% | 0.00% | -9.82% | -19.68% | -28.68% |
| EPS Basic | 23.91% | 17.22% | 4.30% | -7.32% | -3.87% |
| Normalized Basic EPS | 23.92% | 17.23% | 4.30% | -7.33% | -3.88% |
| EPS Diluted | 23.91% | 17.22% | 4.30% | -7.32% | -3.87% |
| Normalized Diluted EPS | 23.92% | 17.23% | 4.30% | -7.33% | -3.88% |
| Average Basic Shares Outstanding | 36.29% | 25.75% | 19.97% | 14.97% | 24.01% |
| Average Diluted Shares Outstanding | 36.29% | 25.75% | 19.97% | 14.97% | 24.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |